Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196)
China
· Delayed Price · Currency is CNY 22.51
-0.31 (-1.36%)
Sep 6, 2024, 3:00 PM CST
Shanghai Fosun Pharmaceutical (Group) Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 39,998 | 40,911 | 43,377 | 38,666 | 29,910 | 28,351 | Upgrade
|
| Other Revenue | 468.83 | 488.71 | 574.48 | 345.58 | 396.96 | 234.4 | Upgrade
|
| Revenue | 40,467 | 41,400 | 43,952 | 39,011 | 30,307 | 28,585 | Upgrade
|
| Revenue Growth (YoY) | -8.03% | -5.81% | 12.66% | 28.72% | 6.02% | 14.72% | Upgrade
|
| Cost of Revenue | 21,479 | 21,717 | 23,256 | 20,294 | 13,798 | 11,556 | Upgrade
|
| Gross Profit | 18,988 | 19,683 | 20,696 | 18,717 | 16,509 | 17,029 | Upgrade
|
| Selling, General & Admin | 13,302 | 14,087 | 12,999 | 12,328 | 11,124 | 12,438 | Upgrade
|
| Research & Development | 4,074 | 4,346 | 4,302 | 3,837 | 2,795 | 2,041 | Upgrade
|
| Other Operating Expenses | 104.27 | -44.99 | -88.15 | -57.86 | -108.24 | 84.64 | Upgrade
|
| Operating Expenses | 17,571 | 18,499 | 17,275 | 16,180 | 13,891 | 14,650 | Upgrade
|
| Operating Income | 1,417 | 1,184 | 3,420 | 2,537 | 2,618 | 2,380 | Upgrade
|
| Interest Expense | -1,431 | -1,325 | -963.81 | -822.54 | -880.95 | -1,075 | Upgrade
|
| Interest & Investment Income | 3,471 | 3,866 | 4,660 | 4,858 | 2,484 | 3,752 | Upgrade
|
| Currency Exchange Gain (Loss) | 59.15 | 13.03 | 62.36 | 154.63 | -24.79 | 40.76 | Upgrade
|
| Other Non Operating Income (Expenses) | -25.7 | -57.73 | -31.78 | -31.06 | -81.16 | -50.7 | Upgrade
|
| EBT Excluding Unusual Items | 3,491 | 3,680 | 7,147 | 6,695 | 4,115 | 5,047 | Upgrade
|
| Impairment of Goodwill | - | - | -180 | -150 | - | -75 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,097 | -488.66 | -2,498 | -110.19 | 494.8 | -650.79 | Upgrade
|
| Gain (Loss) on Sale of Assets | 5.48 | 5.56 | 125.6 | -15.42 | 5.71 | 17.73 | Upgrade
|
| Asset Writedown | -33.36 | -42.14 | -20.48 | -171.01 | -10.11 | -14.98 | Upgrade
|
| Other Unusual Items | 161.68 | 109.38 | 0.25 | -206.16 | 72.71 | 201.59 | Upgrade
|
| Pretax Income | 2,540 | 3,265 | 4,574 | 6,043 | 4,678 | 4,526 | Upgrade
|
| Income Tax Expense | 140.73 | 369.5 | 626.92 | 1,066 | 737.86 | 782.23 | Upgrade
|
| Earnings From Continuing Operations | 2,400 | 2,895 | 3,947 | 4,976 | 3,940 | 3,744 | Upgrade
|
| Minority Interest in Earnings | -565.98 | -508.8 | -216.66 | -247.56 | -277.17 | -421.9 | Upgrade
|
| Net Income | 1,834 | 2,386 | 3,731 | 4,729 | 3,663 | 3,322 | Upgrade
|
| Preferred Dividends & Other Adjustments | -1.05 | - | - | - | - | - | Upgrade
|
| Net Income to Common | 1,835 | 2,386 | 3,731 | 4,729 | 3,663 | 3,322 | Upgrade
|
| Net Income Growth | -53.84% | -36.04% | -21.10% | 29.10% | 10.27% | 22.66% | Upgrade
|
| Shares Outstanding (Basic) | 2,671 | 2,670 | 2,607 | 2,563 | 2,563 | 2,563 | Upgrade
|
| Shares Outstanding (Diluted) | 2,671 | 2,670 | 2,607 | 2,563 | 2,563 | 2,563 | Upgrade
|
| Shares Change (YoY) | 0.40% | 2.40% | 1.74% | - | - | 1.57% | Upgrade
|
| EPS (Basic) | 0.69 | 0.89 | 1.43 | 1.85 | 1.43 | 1.30 | Upgrade
|
| EPS (Diluted) | 0.68 | 0.89 | 1.43 | 1.85 | 1.43 | 1.30 | Upgrade
|
| EPS Growth | -54.43% | -37.76% | -22.50% | 29.10% | 10.27% | 21.13% | Upgrade
|
| Free Cash Flow | -976.29 | -1,922 | -1,671 | -1,035 | -1,857 | -739.65 | Upgrade
|
| Free Cash Flow Per Share | -0.37 | -0.72 | -0.64 | -0.40 | -0.72 | -0.29 | Upgrade
|
| Dividend Per Share | 0.270 | 0.270 | 0.420 | 0.560 | 0.430 | 0.390 | Upgrade
|
| Dividend Growth | -35.71% | -35.71% | -25.00% | 30.23% | 10.26% | 21.88% | Upgrade
|
| Gross Margin | 46.92% | 47.54% | 47.09% | 47.98% | 54.47% | 59.57% | Upgrade
|
| Operating Margin | 3.50% | 2.86% | 7.78% | 6.50% | 8.64% | 8.32% | Upgrade
|
| Profit Margin | 4.53% | 5.76% | 8.49% | 12.12% | 12.09% | 11.62% | Upgrade
|
| Free Cash Flow Margin | -2.41% | -4.64% | -3.80% | -2.65% | -6.13% | -2.59% | Upgrade
|
| EBITDA | 3,448 | 3,838 | 5,541 | 4,184 | 4,083 | 3,676 | Upgrade
|
| EBITDA Margin | 8.52% | 9.27% | 12.61% | 10.72% | 13.47% | 12.86% | Upgrade
|
| D&A For EBITDA | 2,030 | 2,653 | 2,121 | 1,647 | 1,465 | 1,296 | Upgrade
|
| EBIT | 1,417 | 1,184 | 3,420 | 2,537 | 2,618 | 2,380 | Upgrade
|
| EBIT Margin | 3.50% | 2.86% | 7.78% | 6.50% | 8.64% | 8.32% | Upgrade
|
| Effective Tax Rate | 5.54% | 11.32% | 13.70% | 17.65% | 15.77% | 17.28% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.